View article

We read with interest Reddy et al’s angiographic and clinical results of bare metal stents (BMS) and drugeluting stents (DES) for the treatment of stenotic epicardial vasculopathy after heart transplantation (HTx). 1 In their study of 42 patients, they found angiographic and clinical outcomes to be similar at 1 year after intervention and concluded that DES are not superior to BMS in preventing adverse outcomes. We agree with the authors that the small patient population (n 42) is a major study limitation, and we would appreciate comments from Reddy and colleagues on the following suggestions.

With reference to our own experience2 we agree with the authors that there seems to be no advantage of DES over BMS in vasculopathy. However, conclusions should be drawn with caution due to the limited number of clinical end-points (2 cardiac deaths in each group). The comparability of the BMS group with the DES …